Martínez SC, Martínez RJ

Language: Spanish
References: 16
Page: 179-185
PDF size: 86.70 Kb.

ABSTRACT

In the systemic arterial hypertension treatment, left ventricular work overload is to be considered. Therapeutic approach of this circumstance consists in reducing vascular resistance and protecting cardiac myocites.

REFERENCES

1. Grossman W, Jones D, Mchaurin LP: Wall Stress and Patterns of Hipertrophy in The Human Left Ventricle. J Clin Invest 1975; 56: 56-64.

2. Ganau A, Devereux RB, Pickerfering TE, et al: Relation of Left Ventricular Load and Contractile Performance to the Left Ventricular Mass in Hypertension. Circulation 1990; 81: 25-36.

3. Velázquez-Monroy O, Rosas Peralta M, Lara Esqueda A, Pastelíng, Grupo ENSA 2000, Castillo C, Attie F, Tapia Conyer R: Prevalencia e interrelación de enfermedades crónicas no transmisibles y factores de riesgo cardiovascular en México: Resultados finales de la Encuesta Nacional de Salud (ENSA) 2000. Arch Cardiol Mex 2003; 73: 62-77.

4. Lip G, Lee WK: Epidemiología. Tensión Arterial “Normal alta” en Hipertensión. Year Book Lip Co. 2003, Capítulo 1, pp 3-34. ISBN 1-90 4392-00-8, 2003.

5. Devereux RB, Roman MJ, Ganav, et al: Cardiac and Arterial Hipertrophy and ateroesclerosis in hypertension. Hypertension 1994; 23: 802-809.

6. Weber KT, Brilla CG: Pathological Hypertrophy and Cardiac Interstitium. Fibrosis and Renin-Angiotensin-Aldosterone System. Circulation 1991; 83: 1849-1965 (Review).

7. Badeer MS: Biological Significant of Cardiac Hypertrophy. Am J Cardiol 1964; 14: 133-137.

8. Douglas PS, Katz SE, Weinberg EO, et al: Hypertrophic Remodeling: Generer Differens in The Early Response to Left Ventricular Pressure Overload. J Am Coll Cardiol 1998; 32: 1118-1125.

9. The Solud Investigators. Effect of Emalapar on Survival in Patients With Reduces Left Ventricular Ejection Fractions and Congestive Heart Failure. N Engl J Med 1991; 325: 293-302.

10. Cohn JN, Tognoni G: For valheft investigators. The Effect of the Angiotensin Receptor Blocker Valsartan on Morbidity and Mortality in Heart Failure. The Valsartan Heart Failure Trial (Val HeFT). Circulation 2000; 102: 2672B.

11. 11A. MERIT-HF. Study Group. Effect of metoprolol CR/XL in Chronic heart Failure: Metoprolol CR/XL Randomized intervention Trial in Congestive heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.

12. 11B. Colucci WS, Packer M, Bristow MR, et al: For the US Carvedilol Heart Failure Study. Carvendilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996; 94: 2800-2806.

13. Quibrera IR: Concepto e Historia del Síndrome Metabólico. Capítulo 1. Síndrome metabólico y Enfermedad Cardiovascular 2004. Editorial Intersistemas. pp. 1-6.

14. Etgan GT: A tailored therapy for the metabolic syndrome. Diabetes: 2002; 51: 1057-1083.

15. Reaven G: Metabolic syndrome. Pathophysiology and implications of cardiovascular disease. Circulation 2002; 106: 286-288.

16. Packer M: The neurohumoral Hypothesis: A Theory to Explain the Mechanism of Disease progression in heart failure. J Am Coll Cardiol 1992; 20: 248-254.